Entrectinib - NTRK fusion positive solid tumours
You are here : Home > Formulary Search > Entrectinib - NTRK fusion positive solid tumours
I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
Documentation
PAD Profile
ChemicalSubstance :
Entrectinib
Indication :
NTRK fusion positive solid tumours
Group Name :
Keywords :
Cancer,
Brand Names Include :
Rozlytrek
Important Information :
NICE TERMINATED APPRAISAL
This drug has not been assessed for formulary status.
NICE is unable to make a recommendation because the company has not provided an evidence submission. As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug it is recommended that clinicians contact their formulary team to discuss possible alternatives/options
Latest Additions Date From :
04 Feb 2026
Latest Additions Date To :
04 Mar 2026
Guidelines :
Supporting Documents :
1
Committee Recommendations (0)
- No records returned.
Other Indications
Below are listed other indications that Entrectinib is used to treat.
- No records returned.
Other Drugs
Below are listed other drugs that are used to treat NTRK fusion positive solid tumours.
- No records returned.